EP0206533A3
Platelet inhibiting monoclonal antibody fragment
Abstract
There is provided a novel monoclonal antibody fragment which inhibits platelets function and may be useful in the treatment of thrombotic diseases. The fragment is produced by proteolytic digestion of the 7E3 monoclonal antibody.
Term
Term ended
Projected expiry passed 23 May 2006, 20.3 years ago.
- Priority
- Filed
- Published
- Projected expiry
- Today
Every citation, both ways
| Document | Relation | Office | Category | Cited during |
|---|---|---|---|---|
| US4489710A | Cites | United States of America | Y | Search report |
18 members in 7 offices
Priority claims8
| Document | Office | Kind | Date |
|---|---|---|---|
| 745415 | United States of America | – | |
| 74541585 | United States of America | A | |
| 851711 | United States of America | – | |
| 85171186 | United States of America | A | |
| 745415 | – | – | – |
| 851711 | – | – | – |
| US19850745415 | – | – | – |
| US19860851711 | – | – | – |
Members18
| Document | Office | Kind | |
|---|---|---|---|
| EP0206532A2 | European Patent Office (EPO) | A2 | |
| EP0206533A2 | European Patent Office (EPO) | A2 | |
| JPS6229995A | Japan | A | |
| JPS6230728A | Japan | A | |
| EP0206532A3 | European Patent Office (EPO) | A3 | |
| EP0206533A3This record | European Patent Office (EPO) | A3 | |
| CA1297815C | Canada | C | |
| CA1297816C | Canada | C | |
| US5275812A | United States of America | A | |
| EP0206533B1 | European Patent Office (EPO) | B1 | |
| AT104316T | Austria | T | |
| DE3689779D1 | Germany | D1 | |
| US5336618A | United States of America | A | |
| DE3689779T2 | Germany | T2 | |
| US5387413A | United States of America | A | |
| US5440020A | United States of America | A | |
| JP2524978B2 | Japan | B2 | |
| HK1007746A1 | Hong Kong, China | A1 |
37 legal events, as 3 offices reported them to INPADOC
Over the term
Point at a mark for the eventEvents
| Event | Code | Office | |
|---|---|---|---|
| Be: patent expiredExpiredBE20 | BE20 | EP | |
| Nl: ceased due to reaching the maximum lifetime of a patentCeasedNLV7 | NLV7 | EP | |
| Se: european patent has lapsedLapsedEUG | EUG | EP | |
| Patent ceasedCeasedPL | PL | CH | |
| Patent expired after termination of 20 yearsExpiredPE20 | PE20 | GB | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| European patent in force as of 2002-01-01IF02 | IF02 | GB | |
| Correction of patent specification (complete document) publishedK2C3 | K2C3 | EP | |
| No opposition filedOpposition26N | 26N | EP | |
| No opposition filed within time limitOppositionORIGINAL CODE: 0009261PLBE | PLBE | EP | |
| Information on the status of an ep patent application or granted ep patentGrantedSTATUS: NO OPPOSITION FILED WITHIN TIME LIMITSTAA | STAA | EP | |
| Se: european patent in force in swedenEAL | EAL | EP | |
| Fr: translation filedET | ET | EP | |
| Lu: last paid annual feeEPTA | EPTA | EP | |
| It: translation for a ep patent filedITF | ITF | EP | |
| It: translation for a ep patent filedITF | ITF | EP | |
| Corresponds to:REF | REF | EP | |
| Designated contracting statesAK | AK | EP | |
| Corresponds to:REF | REF | EP | |
| (expected) grantORIGINAL CODE: 0009210GRAA | GRAA | EP | |
| First examination report despatched17Q | 17Q | EP | |
| Request for examination filed17P | 17P | EP | |
| Designated contracting statesAK | AK | EP | |
| Search report despatchedORIGINAL CODE: 0009013PUAL | PUAL | EP | |
| Designated contracting statesAK | AK | EP | |
| Public reference made under article 153(3) epc to a published international application that has entered the european phaseORIGINAL CODE: 0009012PUAI | PUAI | EP |
Numbers
- Publication
- 0206533
- Publication, DOCDB
- 0206533
- Publication, EPODOC
- EP0206533
- Application
- 86303955
- Application, DOCDB
- 86303955
- Application, EPODOC
- EP19860303955
Titles3
- English
- Platelet inhibiting monoclonal antibody fragment
- French
- Fragment d'anticorps monoclonal inhibant les plaquettes
- German
- Plättcheninhibierender Teil eines monoklonalen Antikörpers
Classification
- CPC, 3
- C07K16/28
- A61K38/00
- A61P7/02
- IPC, 15
- C12N5 10
- A61K38 00
- A61K39 395
- A61P7 02
- C07K1 22
- C07K14 005
- C07K14 195
- C07K16 00
- C07K16 28
- C12N5 00
- C12N15 00
- C12N15 02
- C12P21 00
- C12P21 08
- C12R1 91
Designated states11
- Contracting states, 11
- Austria
- Belgium
- Switzerland
- Germany
- France
- United Kingdom
- Italy
- Liechtenstein
- Luxembourg
- Netherlands (Kingdom of the)
- Sweden